Thursday, 15 October 2026European Markets

European Markets

5 articles

UK Gilt Yields Hit 5.10% as Starmer Rebellion Spreads Contagion to EU Markets

UK Gilt Yields Hit 5.10% as Starmer Rebellion Spreads Contagion to EU Markets

UK gilt yields surged to 5.10% in mid-May 2026, driving equity sell-offs across UK and European markets. Sterling's sharp decline against the euro reflects a crisis-of-confidence feedback loop as Starmer faces an 80+ MP rebellion and JPMorgan warns of a 3–5% banking surcharge. With Fed futures pricing only a 1-in-3 chance of a US rate cut in 2026, the higher-for-longer global rate backdrop leaves EU markets exposed.

LM Salvado•
Gold at $4,200/oz Drives EU Mining Expansions as UK Instability Fuels Safe-Haven Demand

Gold at $4,200/oz Drives EU Mining Expansions as UK Instability Fuels Safe-Haven Demand

Gold futures hit record $4,200/oz in November 2026 as UK political turmoil and tech sector losses drove European investors to precious metals. Mining firms across the EU region are accelerating expansion projects to capture elevated prices, with Fortuna Mining advancing Senegal's Diamba Sud and boosting production guidance 1-9% for 2026.

ViaNews Editorial Team (Europe)•
Euro Hits 20-Month High Against Pound as UK Budget Concerns Mount

Euro Hits 20-Month High Against Pound as UK Budget Concerns Mount

The British pound fell 0.4% to €1.13, its lowest level since April 2023, as currency markets anticipate further weakness ahead of the UK's November 26 budget. The euro's strength against sterling creates favorable conditions for European exporters and investors with UK exposure, while analysts forecast GBP could breach $1.30.

ViaNews Editorial Team (Europe)•
Euro Gains 14% Against Dollar as US Currency Hits Lowest Level Since 2022

Euro Gains 14% Against Dollar as US Currency Hits Lowest Level Since 2022

The euro has climbed 14% against the US dollar in 2025, while the British pound gained 7%, as the greenback fell to its lowest level since 2022. The currency realignment occurs amid upcoming Fed leadership changes and geopolitical shifts including US-Iran nuclear deal progress.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com